Halozyme Therapeutics, Inc. (HALO) fundamentals score
As the innovators of ENHANZE drug delivery technology (“ENHANZE”) with its proprietary enzyme, rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (“SC”) delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden.
Biological Products, (No Diagnostic Substances) · Healthcare · Listed on NASDAQ
Overall: 7.2 out of 10, Good long-term fundamentals
- Growth: 7.0/10
- Profitability: 7.5/10
- Financial health: 7.2/10
- Earnings quality: 9.3/10
- Valuation: 4.9/10
Scores are calculated from Halozyme Therapeutics, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10